Eli Lilly and Company (NYSE:LLY) Position Boosted by Stock Yards Bank & Trust Co.

Stock Yards Bank & Trust Co. raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 0.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 110,957 shares of the company's stock after purchasing an additional 581 shares during the period. Eli Lilly and Company accounts for approximately 3.3% of Stock Yards Bank & Trust Co.'s investment portfolio, making the stock its 3rd biggest position. Stock Yards Bank & Trust Co.'s holdings in Eli Lilly and Company were worth $91,641,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Knightsbridge Asset Management LLC lifted its stake in Eli Lilly and Company by 1.9% in the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock valued at $628,000 after buying an additional 15 shares during the period. Centerpoint Advisory Group bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at $514,000. LS Investment Advisors LLC increased its position in shares of Eli Lilly and Company by 1.7% during the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after acquiring an additional 40 shares in the last quarter. Kentucky Trust Co acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $834,000. Finally, CSM Advisors LLC boosted its stake in Eli Lilly and Company by 30.6% during the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock valued at $807,000 after purchasing an additional 245 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on LLY. Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target on the stock. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their target price for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, UBS Group decreased their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.37.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $11.74 on Monday, reaching $807.62. The stock had a trading volume of 2,819,360 shares, compared to its average volume of 3,654,958. The business's 50 day moving average is $777.10 and its two-hundred day moving average is $801.77. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a market cap of $765.41 billion, a P/E ratio of 68.97, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. During the same quarter last year, the firm earned $2.58 earnings per share. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.74%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company's payout ratio is 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.